BioSpace News Archive

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, reported first quarter 2023 financial results and recent portfolio updates.

DBV Technologies announced that its Phase 3 EPITOPE trial of epicutaneous immunotherapy with Viaskin™ Peanut in children 1 – 3 years was published in the New England Journal of Medicine, reinforcing the potential of a new food allergy treatment option for this community.

Aemetis, Inc. (NASDAQ: AMTX): Stonegate Capital Partners updates coverage on Aemetis, Inc. (NASDAQ: AMTX). The full report can be accessed by clicking on the following link: Aemetis, Inc. Q1 2023 Report

NCIB will commence on May 15, 2023 and is expected to continue through the debentures’ October 2023 maturity date

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.

Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the novel R21/Matrix-MTM Malaria Vaccine by the Ghana Food and Drugs Authority (FDA) for use in children as young as 5 months old up to 36 months old, in Ghana.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments.

Blue Water Biotech, Inc. announced that Blue Water management will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15th at 3:30pm EDT.

Stryker announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable July 31, 2023 to shareholders of record at the close of business on June 30, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter.

Bracco Imaging announced that the American College of Radiology has classified VUEWAY® as a Group II agent within its classification of gadolinium-based contrast agents relative to the risk of development of nephrogenic systemic fibrosis.2